Cancer is one of the leading causes of death worldwide, and multiple genetic mutations lead to cell mutations that result in the development of malignant tumors. Although surgery, radiotherapy, and standard chemotherapy remain the mainstay of treatment, these treatments usually also have a detrimental effect on healthy cells.
The development of genetic engineering technology in the 19th century led to a series of breakthroughs in therapeutic protein drugs, and the launch of the world's first recombinant protein drug, recombinant human insulin, in 1982, initiated the development of therapeutic protein drugs.
Therapeutic proteins are the fastest growing class of protein drugs used in a variety of clinical settings, including cancer, chronic inflammatory diseases, kidney transplantation, cardiovascular medicine, and infectious diseases. There are seven main categories: peptide hormones, cytokines, plasma protein factors, recombinant enzymes, fusion proteins, monoclonal antibodies, and others.
Therapeutic proteins include the use of genetic engineering technology to modify "engineered bacteria" or "engineered cells" to express human functional proteins or their mutants in bulk to compensate for the lack of functional proteins in the body caused by congenital genetic defects or acquired diseases.
Cancer patients' bodies need white blood cells and other immune system cells to fight disease and foreign invaders, but because chemotherapy, radiation, and other cancer treatments make it difficult for the body to make new blood cells, cancer patients are often more susceptible to infection.
- Colony-stimulating factor (CSF), a therapeutic protein, promotes the production of more blood cells by stem cells in the bone marrow, which, through proper cell production, allows cancer patients to tolerate more cancer treatments.
- In addition, interferon (IFN) is a therapeutic protein that helps the body fight viral infections and cancer. IFN-α enhances the ability of certain immune cells to attack cancer cells. IFN also inhibits the growth of cancer cells and the blood vessels needed for tumor growth.
- Interleukin (IL) is also a therapeutic protein that helps white blood cells communicate and trigger immune system responses. Laboratory-made IL-2 is used to treat advanced kidney cancer and metastatic melanoma. IL-2 can also be used in combination with chemotherapy or other biotherapeutic agents, such as IFN-α, to treat cancer.
Therapeutic proteins have revolutionized the treatment method of many diseases, including many highly prevalent cancers, and it is expected that more therapeutic proteins will be available shortly for an increasingly wide range of indications. Creative BioMart focuses on the tremendous potential of therapeutic proteins in cancer therapy and is committed to providing highly therapeutic protein products to researchers in cancer therapy and molecular mechanics. We can customize product development solutions to combine your needs and project direction to best meet your research needs. Please contact our staff for a custom solution and an up-to-date quote.